StockNews.com upgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA – Free Report) from a hold rating to a buy rating ...
Teva Pharmaceutical Industries (NYSE:TEVA) saw its stock price move up 14% over the last week, a notable jump attributed ...
The general mood among these heavyweight investors is divided, with 44% leaning bullish and 33% bearish. Among these notable options, 5 are puts, totaling $256,004, and 4 are calls, amounting to ...
Investor's Business Daily on MSN3d
Teva Pharmaceutical Stock Scores RS Rating UpgradeTeva Pharmaceutical ADR shows improving price performance, earning an upgrade to its IBD Relative Strength Rating ...
Stanley Druckenmiller, whose net worth is around $6.9 billion, made most of his fortune as a hedge fund manager, and became a ...
NEW YORK, NY / ACCESS Newswire / March 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Corcept ...
HighTower Advisors LLC raised its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 32.3% in ...
The global pharmaceutical company Teva announced a strategic partnership with Kerry Pharma, a subsidiary of the Kerry ...
Pharmaceutical Technology on MSN2d
Sacklers to pay up to $7bn in Purdue Pharma’s opioid settlement planPurdue is expected to raise and contribute $900m while dissolving and transforming into a new public benefit company. The non ...
In a report released today, David Amsellem from Piper Sandler maintained a Buy rating on Amneal Pharmaceuticals (AMRX – Research Report), with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback